Lipoprotein Particle Profiles, Standard Lipids, and Peripheral Artery Disease Incidence: Prospective Data From the Women’s Health Study
暂无分享,去创建一个
[1] Lawrence A Leiter,et al. Inflammatory and Cholesterol Risk in the FOURIER Trial , 2018, Circulation.
[2] P. Wilson,et al. Association of Statin Dose With Amputation and Survival in Patients With Peripheral Artery Disease , 2018, Circulation.
[3] Marc P. Bonaca,et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) , 2017, Circulation.
[4] Audrey Y. Chu,et al. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low‐Density Lipoprotein Cholesterol , 2017, Journal of the American Heart Association.
[5] Ž. Reiner. Hypertriglyceridaemia and risk of coronary artery disease , 2017, Nature Reviews Cardiology.
[6] L. Pérez de Isla,et al. Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia: Insights From the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study) , 2016, Arteriosclerosis, thrombosis, and vascular biology.
[7] R. Hegele,et al. Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol , 2016, Diabetes.
[8] N. Paynter,et al. Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial. , 2016, JAMA cardiology.
[9] A. Pereira,et al. Peripheral arterial disease in heterozygous familial hypercholesterolemia. , 2015, Atherosclerosis.
[10] V. Aboyans,et al. Epidemiology of peripheral artery disease. , 2015, Circulation research.
[11] Deepak L. Bhatt,et al. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. , 2014, European heart journal.
[12] W. Krone,et al. Effects of Lipid-Lowering Drugs on High-Density Lipoprotein Subclasses in Healthy Men—A Randomized Trial , 2014, PloS one.
[13] M. Blaha,et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. , 2013, JAMA.
[14] V. Aboyans,et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. , 2012, Circulation.
[15] N. Paynter,et al. Lipoprotein subclass abnormalities and incident hypertension in initially healthy women. , 2011, Clinical chemistry.
[16] J. Borén,et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management , 2011, European heart journal.
[17] P. Ridker,et al. Lipoprotein Particle Size and Concentration by Nuclear Magnetic Resonance and Incident Type 2 Diabetes in Women , 2010, Diabetes.
[18] P. Ridker,et al. Metabolic Syndrome, Inflammation, and Risk of Symptomatic Peripheral Artery Disease in Women: A Prospective Study , 2009, Circulation.
[19] J. Després,et al. HDL particle size and the risk of coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. , 2009, Atherosclerosis.
[20] Børge G Nordestgaard,et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial , 2009, The Lancet.
[21] Samia Mora,et al. Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women , 2009, Circulation.
[22] A. Frasheri,et al. Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease. , 2008, Atherosclerosis.
[23] Michael J Pencina,et al. LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management. , 2007, Journal of clinical lipidology.
[24] Inder Singh,et al. High-density lipoprotein as a therapeutic target: a systematic review. , 2007, JAMA.
[25] Moyses Szklo,et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). , 2007, Atherosclerosis.
[26] Nicholas J Wareham,et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. , 2007, Journal of the American College of Cardiology.
[27] W. Cromwell,et al. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. , 2006, Clinics in laboratory medicine.
[28] A. Folsom,et al. The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA). , 2006, Journal of the American College of Cardiology.
[29] H. Bloomfield,et al. Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial , 2006, Circulation.
[30] R. D'Agostino,et al. Increased Small Low-Density Lipoprotein Particle Number: A Prominent Feature of the Metabolic Syndrome in the Framingham Heart Study , 2005, Circulation.
[31] J. Polak,et al. Risk factors for declining ankle-brachial index in men and women 65 years or older: the Cardiovascular Health Study. , 2005, Archives of internal medicine.
[32] Ken Williams,et al. Nuclear Magnetic Resonance Lipoprotein Abnormalities in Prediabetic Subjects in the Insulin Resistance Atherosclerosis Study , 2005, Circulation.
[33] J. Manson,et al. A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women , 2005, The New England journal of medicine.
[34] A. Jenkins,et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. , 2003, Diabetes.
[35] T. Meade,et al. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial , 2002, BMJ : British Medical Journal.
[36] W. Cromwell,et al. Measurement issues related to lipoprotein heterogeneity. , 2002, The American journal of cardiology.
[37] P. Ridker,et al. Low-Density Lipoprotein Particle Concentration and Size as Determined by Nuclear Magnetic Resonance Spectroscopy as Predictors of Cardiovascular Disease in Women , 2002, Circulation.
[38] Alice Arnold,et al. Nuclear Magnetic Resonance Spectroscopy of Lipoproteins and Risk of Coronary Heart Disease in the Cardiovascular Health Study , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[39] J. Murabito,et al. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. , 2002, American heart journal.
[40] J. Després,et al. Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. , 2001, Journal of lipid research.
[41] N Rifai,et al. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. , 2001, JAMA.
[42] A. Hofman,et al. Determinants of peripheral arterial disease in the elderly: the Rotterdam study. , 2000, Archives of internal medicine.
[43] J. Manson,et al. Homocysteine and risk of cardiovascular disease among postmenopausal women. , 1999, JAMA.
[44] R B D'Agostino,et al. Intermittent claudication. A risk profile from The Framingham Heart Study. , 1997, Circulation.
[45] N. Poulter,et al. The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of critical ischaemia. , 1996, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.
[46] P. Elwood,et al. Peripheral vascular disease: consequence for survival and association with risk factors in the Speedwell prospective heart disease study. , 1994, British heart journal.
[47] F. Fowkes,et al. The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys. , 1992, Journal of clinical epidemiology.
[48] R. Prescott,et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. , 1992, American journal of epidemiology.
[49] J. Beaumont,et al. Ischaemic disease in men and women with familial hypercholesterolaemia and xanthomatosis. A comparative study of genetic and environmental factors in 274 heterozygous cases. , 1976, Atherosclerosis.
[50] M. Szklo,et al. The Multi-Ethnic Study of Atherosclerosis (MESA) , 2012 .
[51] J. Lewicki,et al. Lipid levels and peripheral vascular disease in diabetic and non-diabetic subjects. , 1998, Atherosclerosis.